Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Recent commentary ties these price target moves directly to how Journey Medical contributes to Fortress’s asset base, while core modeling inputs such as fair value at $13.50, a 7.108% discount rate, 46.87% revenue growth, 25.61% net profit margin, and a 10.43x future P/E are held steady. Ahead, you will see how to track this evolving narrative and what it may mean for your own view on Journey Medical.
